Display options
Cite
White JM, Schiffer JT, Bender Ignacio RA, et al. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio. 2021;12(6):e0334721doi: 10.1128/mbio.03347-21.
White, J. M., Schiffer, J. T., Bender Ignacio, R. A., Xu, S., Kainov, D., Ianevski, A., Aittokallio, T., Frieman, M., Olinger, G. G., & Polyak, S. J. (2021). Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio, 12(6), e0334721. https://doi.org/10.1128/mbio.03347-21
White, Judith M, et al. "Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses." mBio vol. 12,6 (2021): e0334721. doi: https://doi.org/10.1128/mbio.03347-21
White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio. 2021 Dec 21;12(6):e0334721. doi: 10.1128/mbio.03347-21. Epub 2021 Dec 21. PMID: 34933447; PMCID: PMC8689562.
Copy Download .nbib Format: NLM
Share it on

mBio. 2021 Dec 21;12(6):e0334721. doi: 10.1128/mbio.03347-21. Epub 2021 Dec 21.

Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.

mBio

Judith M White, Joshua T Schiffer, Rachel A Bender Ignacio, Shuang Xu, Denis Kainov, Aleksandr Ianevski, Tero Aittokallio, Matthew Frieman, Gene G Olinger, Stephen J Polyak

Affiliations

  1. University of Virginiagrid.27755.32, Department of Cell Biology, Charlottesville, Virginia, USA.
  2. University of Virginiagrid.27755.32, Department of Microbiology, Charlottesville, Virginia, USA.
  3. University of Washington, Division of Allergy and Infectious Diseases, Seattle, Washington, USA.
  4. Fred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, Washington, USA.
  5. Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  6. Institute of Technology, University of Tartu, Tartu, Estonia.
  7. Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
  8. Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo, Oslo, Norway.
  9. Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  10. Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  11. MRIGlobal, Gaithersburg, Maryland, USA.
  12. Virology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  13. Department of Global Health, University of Washington, Seattle, Washington, USA.
  14. Department of Microbiology, University of Washington, Seattle, Washington, USA.

PMID: 34933447 PMCID: PMC8689562 DOI: 10.1128/mbio.03347-21

Abstract

The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-equipped for future pandemics. While unprecedented strides have been made developing vaccines and treatments for COVID-19, there remains a need for highly effective and widely available regimens for ambulatory use for novel coronaviruses and other viral pathogens. We posit that a priority is to develop pan-family drug cocktails to enhance potency, limit toxicity, and avoid drug resistance. We urge cocktail development for all viruses with pandemic potential both in the short term (<1 to 2 years) and longer term with pairs of drugs in advanced clinical testing or repurposed agents approved for other indications. While significant efforts were launched against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),

Keywords: COVID-19; Ebola virus; SARS-CoV-2; antiviral drugs; category A-C pathogens; countermeasures; drug synergy; early treatment; model-driven approach; pandemic preparedness; prophylaxis; viral pandemic

References

  1. Viruses. 2020 Oct 18;12(10): - PubMed
  2. PLoS Pathog. 2021 Sep 17;17(9):e1009929 - PubMed
  3. Ther Clin Risk Manag. 2008 Oct;4(5):1023-33 - PubMed
  4. Antimicrob Agents Chemother. 2021 Mar 18;65(4): - PubMed
  5. Nat Commun. 2020 Sep 4;11(1):4417 - PubMed
  6. Science. 2021 Dec 2;:eabj5508 - PubMed
  7. Clin Ther. 2015 Sep 1;37(9):1876-93 - PubMed
  8. J Virol. 2020 Oct 14;94(21): - PubMed
  9. PLoS Comput Biol. 2020 Feb 3;16(2):e1007604 - PubMed
  10. N Engl J Med. 2021 Feb 25;384(8):693-704 - PubMed
  11. JAMA. 2020 Dec 8;324(22):2292-2300 - PubMed
  12. N Engl J Med. 2021 Feb 11;384(6):497-511 - PubMed
  13. Viruses. 2020 Jun 13;12(6): - PubMed
  14. J Viral Hepat. 2018 Feb;25(2):118-125 - PubMed
  15. Antiviral Res. 2020 Jun;178:104786 - PubMed
  16. Antimicrob Agents Chemother. 2020 Jun 23;64(7): - PubMed
  17. Biochemistry. 1993 Mar 30;32(12):2967-78 - PubMed
  18. J Virol. 2019 Apr 3;93(8): - PubMed
  19. J Clin Invest. 2017 Apr 3;127(4):1338-1352 - PubMed
  20. JCI Insight. 2017 Mar 23;2(6):e88864 - PubMed
  21. Lancet. 2020 May 30;395(10238):1695-1704 - PubMed
  22. J Virol. 2014 Jul;88(13):7294-306 - PubMed
  23. Cell Rep. 2021 Apr 6;35(1):108959 - PubMed
  24. Viruses. 2021 Jun 27;13(7): - PubMed
  25. Curr Opin Virol. 2021 Apr;47:113-120 - PubMed
  26. J Infect Dis. 2021 Aug 2;224(3):415-419 - PubMed
  27. Nat Med. 2012 Feb 19;18(3):446-51 - PubMed
  28. Proc Natl Acad Sci U S A. 2021 Jul 27;118(30): - PubMed
  29. mBio. 2021 Aug 31;12(4):e0097021 - PubMed
  30. Curr Opin Virol. 2021 Aug;49:183-193 - PubMed
  31. J Biol Chem. 2021 Jul;297(1):100770 - PubMed
  32. Science. 2021 Jul 30;373(6554):541-547 - PubMed
  33. Sci Immunol. 2021 May 18;6(59): - PubMed
  34. Mol Cell. 2020 May 21;78(4):779-784.e5 - PubMed
  35. Nat Med. 2012 Sep;18(9):1378-85 - PubMed
  36. Elife. 2019 Aug 27;8: - PubMed
  37. J Cell Sci. 2013 Mar 15;126(Pt 6):1289-95 - PubMed
  38. Nature. 2021 Apr;592(7854):326 - PubMed
  39. J Virol. 2020 Dec 9;95(1): - PubMed
  40. Antimicrob Agents Chemother. 2013 Dec;57(12):5820-9 - PubMed
  41. Viruses. 2021 Jul 20;13(7): - PubMed
  42. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7382-7395 - PubMed
  43. Sci Transl Med. 2017 Jun 28;9(396): - PubMed
  44. Lancet Respir Med. 2020 Sep;8(9):e70 - PubMed
  45. Virology. 2006 Mar 15;346(2):251-7 - PubMed
  46. J Med Chem. 2020 Nov 12;63(21):12359-12386 - PubMed
  47. N Engl J Med. 2021 Jan 21;384(3):229-237 - PubMed
  48. J Virol. 2021 Nov 23;95(24):e0143721 - PubMed
  49. J Clin Invest. 2021 Jan 4;131(1): - PubMed
  50. Mol Cell. 2020 Sep 3;79(5):710-727 - PubMed
  51. Viruses. 2021 Apr 09;13(4): - PubMed
  52. Viruses. 2019 Feb 20;11(2): - PubMed
  53. J Gen Virol. 2021 Jul;102(7): - PubMed
  54. J Clin Invest. 2021 May 17;131(10): - PubMed
  55. Antimicrob Agents Chemother. 2015 Feb;59(2):1061-9 - PubMed
  56. J Biol Chem. 2021 Jan-Jun;296:100701 - PubMed
  57. Science. 2021 Aug 20;373(6557):931-936 - PubMed
  58. Cell Rep. 2021 Aug 3;36(5):109479 - PubMed
  59. Microorganisms. 2021 Mar 10;9(3): - PubMed
  60. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29): - PubMed
  61. J Virol. 2020 Sep 15;94(19): - PubMed
  62. Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0268020 - PubMed
  63. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0115521 - PubMed
  64. Clin Pharmacol Ther. 2021 Jul;110(1):64-68 - PubMed
  65. Nature. 2020 May;581(7809):465-469 - PubMed
  66. Traffic. 2016 Jun;17(6):593-614 - PubMed
  67. Lancet Respir Med. 2021 Dec;9(12):1407-1418 - PubMed
  68. Cell. 2020 Dec 23;183(7):1901-1912.e9 - PubMed
  69. Nat Biotechnol. 2009 Jul;27(7):659-66 - PubMed
  70. N Engl J Med. 2020 Nov 5;383(19):1827-1837 - PubMed
  71. J Virol. 2019 Feb 5;93(4): - PubMed
  72. EMBO J. 2021 Aug 16;40(16):e107821 - PubMed
  73. Science. 2020 Nov 6;370(6517):725-730 - PubMed
  74. Sci Adv. 2020 Nov 20;6(47): - PubMed
  75. Crit Rev Biochem Mol Biol. 2008 May-Jun;43(3):189-219 - PubMed
  76. Nat Med. 2008 Jul;14(7):762-6 - PubMed
  77. J Med Virol. 2021 Mar;93(3):1403-1408 - PubMed
  78. Science. 2021 Feb 26;371(6532):926-931 - PubMed
  79. Sci Transl Med. 2011 Jul 13;3(91):91ra63 - PubMed
  80. Sci Transl Med. 2020 Apr 29;12(541): - PubMed
  81. N Engl J Med. 2021 Nov 18;385(21):1941-1950 - PubMed
  82. Proc Natl Acad Sci U S A. 2021 Oct 26;118(43): - PubMed
  83. J Med Chem. 2018 Feb 8;61(3):724-733 - PubMed
  84. N Engl J Med. 1997 Sep 11;337(11):734-9 - PubMed
  85. Curr Opin Pharmacol. 2019 Oct;48:92-98 - PubMed
  86. N Engl J Med. 2015 Dec 31;373(27):2608-17 - PubMed
  87. Viruses. 2021 Jul 08;13(7): - PubMed
  88. Antimicrob Agents Chemother. 2021 Mar 18;65(4): - PubMed
  89. Comput Struct Biotechnol J. 2015 Sep 25;13:504-13 - PubMed
  90. Antiviral Res. 2021 Aug;192:105115 - PubMed
  91. Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5 - PubMed
  92. Cell. 2020 Aug 6;182(3):685-712.e19 - PubMed
  93. Science. 2020 May 22;368(6493):860-868 - PubMed
  94. Phytomedicine. 2019 Sep;62:152956 - PubMed
  95. N Engl J Med. 2021 Mar 4;384(9):795-807 - PubMed
  96. Antiviral Res. 2020 Sep;181:104878 - PubMed
  97. PLoS Pathog. 2021 Feb 4;17(2):e1009312 - PubMed
  98. Science. 2021 Mar 26;371(6536):1379-1382 - PubMed
  99. Nat Commun. 2021 Jun 3;12(1):3309 - PubMed
  100. JCI Insight. 2021 Nov 22;: - PubMed
  101. Virology. 2022 Jan;566:60-68 - PubMed
  102. J Virol. 2021 May 24;95(12): - PubMed
  103. Nature. 2021 Aug;596(7871):276-280 - PubMed
  104. Nat Microbiol. 2021 Jul;6(7):899-909 - PubMed
  105. Antiviral Res. 2015 Jun;118:148-58 - PubMed
  106. Proc Natl Acad Sci U S A. 2021 Sep 28;118(39): - PubMed
  107. Science. 2021 Dec 24;374(6575):1586-1593 - PubMed
  108. Biomed Pharmacother. 2021 May;137:111313 - PubMed
  109. N Engl J Med. 2021 Aug 5;385(6):562-566 - PubMed
  110. Clin Infect Dis. 2021 Oct 01;: - PubMed
  111. J Infect Dis. 2018 Nov 22;218(suppl_5):S672-S678 - PubMed
  112. Nature. 2021 Mar;591(7850):451-457 - PubMed
  113. N Engl J Med. 2021 Jan 21;384(3):238-251 - PubMed
  114. Nature. 2016 Mar 17;531(7594):381-5 - PubMed
  115. Sci Adv. 2021 Jan 1;7(1): - PubMed
  116. Nature. 1997 May 8;387(6629):188-91 - PubMed
  117. Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):206-214 - PubMed
  118. Nat Microbiol. 2021 Jan;6(1):11-18 - PubMed
  119. J Virol. 2011 Jan;85(2):873-82 - PubMed
  120. Viruses. 2021 Aug 23;13(8): - PubMed
  121. ACS Infect Dis. 2021 Jun 11;7(6):1409-1422 - PubMed
  122. mBio. 2020 Jun 30;11(3): - PubMed
  123. iScience. 2021 Apr 23;24(4):102367 - PubMed
  124. J Virol. 2019 May 29;93(12): - PubMed
  125. PLoS Pathog. 2010 Oct 07;6(10):e1001131 - PubMed
  126. Curr Opin Virol. 2021 Aug;49:36-40 - PubMed
  127. Cell Host Microbe. 2021 Jul 14;29(7):1151-1161.e5 - PubMed
  128. Nat Commun. 2020 Dec 14;11(1):6385 - PubMed
  129. ACS Infect Dis. 2021 Aug 13;7(8):2337-2351 - PubMed
  130. Nat Commun. 2021 Sep 21;12(1):5553 - PubMed
  131. mBio. 2021 Jan 19;12(1): - PubMed
  132. Front Microbiol. 2021 Apr 30;12:651403 - PubMed
  133. Clin Microbiol Rev. 2021 Dec 15;34(4):e0010921 - PubMed
  134. Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30687-30698 - PubMed
  135. PLoS One. 2020 Nov 11;15(11):e0242184 - PubMed
  136. J Clin Invest. 2015 Dec;125(12):4692-8 - PubMed
  137. Sci Transl Med. 2015 Jun 3;7(290):290ra89 - PubMed
  138. Sci Transl Med. 2016 Feb 3;8(324):324ra15 - PubMed
  139. J Infect Dis. 2018 Oct 20;218(11):1691-1699 - PubMed
  140. Ann Intern Med. 2021 Mar;174(3):344-352 - PubMed
  141. EMBO J. 2020 May 18;39(10):e105114 - PubMed
  142. Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12543-7 - PubMed
  143. Cell Rep. 2021 May 18;35(7):109133 - PubMed
  144. Viruses. 2021 Feb 09;13(2): - PubMed
  145. Viruses. 2021 Sep 04;13(9): - PubMed
  146. AIDS. 1999 May 7;13(7):797-804 - PubMed
  147. J Virol. 2021 Oct 13;95(21):e0097521 - PubMed
  148. Sci Transl Med. 2013 Jun 19;5(190):190ra79 - PubMed
  149. PLoS One. 2021 Oct 19;16(10):e0258858 - PubMed
  150. Nature. 2021 Apr;592(7853):277-282 - PubMed
  151. Cell Rep. 2021 Jul 27;36(4):109450 - PubMed
  152. N Engl J Med. 2021 Sep 23;385(13):1184-1195 - PubMed
  153. Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493 - PubMed
  154. Nat Commun. 2021 Sep 17;12(1):5498 - PubMed
  155. Nature. 2021 Apr;592(7854):340-343 - PubMed
  156. N Engl J Med. 2021 Mar 11;384(10):905-914 - PubMed
  157. Signal Transduct Target Ther. 2021 Jul 29;6(1):288 - PubMed
  158. Antiviral Res. 2017 Jan;137:165-172 - PubMed
  159. N Engl J Med. 2021 Oct 7;385(15):1382-1392 - PubMed
  160. Nature. 2021 Aug;596(7873):495-504 - PubMed
  161. Nat Commun. 2021 Nov 5;12(1):6415 - PubMed
  162. N Engl J Med. 2020 Nov 5;383(19):1813-1826 - PubMed
  163. JAMA Netw Open. 2021 Mar 1;4(3):e213071 - PubMed
  164. Lancet Reg Health Eur. 2021 May;4:100084 - PubMed
  165. Cell. 2020 Apr 16;181(2):271-280.e8 - PubMed
  166. PLoS Pathog. 2021 Jun 7;17(6):e1009662 - PubMed
  167. Science. 2020 Dec 18;370(6523):1473-1479 - PubMed
  168. Nat Rev Drug Discov. 2010 Dec;9(12):929-39 - PubMed
  169. EBioMedicine. 2021 May;67:103355 - PubMed
  170. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7613-8 - PubMed
  171. Nat Med. 2021 Mar;27(3):401-410 - PubMed
  172. J Biol Chem. 2020 May 15;295(20):6785-6797 - PubMed
  173. PLoS Negl Trop Dis. 2017 Apr 12;11(4):e0005540 - PubMed
  174. Lancet Glob Health. 2022 Jan;10(1):e42-e51 - PubMed
  175. Mol Ther. 2021 Feb 3;29(2):873-885 - PubMed
  176. Lancet Respir Med. 2021 Feb;9(2):196-206 - PubMed
  177. N Engl J Med. 2020 Dec 3;383(23):2291-2293 - PubMed
  178. J Virol. 1997 Nov;71(11):8808-20 - PubMed
  179. Nature. 2020 Oct;586(7827):113-119 - PubMed
  180. FEBS Open Bio. 2021 May;11(5):1452-1464 - PubMed

Publication Types

Grant support